Circulating microRNAs as potential markers of human drug‐induced liver injury

New biomarkers of liver injury are required in the clinic and in preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver‐enriched microRNAs (miR‐122 and miR‐192) are promising biomarkers of acetaminophen‐induced acute liver injury (APAP‐ALI) in mice. We have examined these...

Full description

Saved in:

Bibliographic Details
Published in:	Hepatology (Baltimore, Md.) Vol. 54; no. 5; pp. 1767 - 1776
Main Authors:	Starkey Lewis, Philip J., Dear, James, Platt, Vivien, Simpson, Kenneth J., Craig, Darren G.N., Antoine, Daniel J., French, Neil S., Dhaun, Neeraj, Webb, David J., Costello, Eithne M., Neoptolemos, John P., Moggs, Jonathan, Goldring, Chris E., Park, B. Kevin
Format:	Journal Article
Language:	English
Published:	Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.11.2011 Wiley Wolters Kluwer Health, Inc
Subjects:	Acetaminophen - poisoning Acute Disease Adolescent Adult Aged Alanine Transaminase - blood Analgesics, Non-Narcotic - poisoning Biological and medical sciences Biomarkers Biomarkers - blood Chemical and Drug Induced Liver Injury - blood Chemical and Drug Induced Liver Injury - diagnosis Chemical and Drug Induced Liver Injury - surgery Diagnostic Techniques, Digestive System Drug toxicity and drugs side effects treatment Female Gastroenterology. Liver. Pancreas. Abdomen Hepatology Humans Liver Liver Transplantation Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences MicroRNAs MicroRNAs - blood Middle Aged Pharmacology. Drug treatments Prospective Studies Toxicity: digestive system Young Adult Human Digestive diseases Hepatic disease Hepatotoxicity Gastroenterology
ISSN:	0270-9139, 1527-3350, 1527-3350
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	New biomarkers of liver injury are required in the clinic and in preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver‐enriched microRNAs (miR‐122 and miR‐192) are promising biomarkers of acetaminophen‐induced acute liver injury (APAP‐ALI) in mice. We have examined these molecules, for the first time, in humans with APAP poisoning. Serum miR‐122 and miR‐192 were substantially higher in APAP‐ALI patients, compared to healthy controls (median ΔΔCt [25th, 75th percentile]) (miR‐122: 1,265 [491, 4,270] versus 12.1 [7.0, 26.9], P < 0.0001; miR‐192: 6.9 [2.0, 29.2] versus 0.44 [0.30, 0.69], P < 0.0001). A heart‐enriched miR‐1 showed no difference between APAP‐ALI patients and controls, whereas miR‐218 (brain‐enriched) was slightly higher in the APAP‐ALI cohort (0.17 [0.07, 0.50] versus 0.07 [0.04, 0.12]; P = 0.01). In chronic kidney disease (CKD) patients, miR‐122 and ‐192 were modestly higher, compared to controls (miR‐122: 32.0 [21.1, 40.9] versus 12.1 [7.0, 26.9], P = 0.006; miR‐192: 1.2 [0.74, 1.9] versus 0.44 [0.30, 0.69], P = 0.005), but miR‐122 and ‐192 were substantially higher in APAP‐ALI patients than CKD patients (miR‐122: P < 0.0001; miR‐192: P < 0.0004). miR‐122 correlated with peak ALT levels in the APAP‐ALI cohort (Pearson R = 0.46, P = 0.0005), but not with prothrombin time. miR‐122 was also raised alongside peak ALT levels in a group of patients with non‐APAP ALI. Day 1 serum miR‐122 levels were almost 2‐fold higher in APAP‐ALI patients who satisfied King's College Criteria (KCC), compared to those who did not satisfy KCC, although this did not reach statistical significance (P = 0.15). Conclusion: This work provides the first evidence for the potential use of miRNAs as biomarkers of human drug‐induced liver injury. (HEPATOLOGY 2011;)
AbstractList	New biomarkers of liver injury are required in the clinic and in preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver-enriched microRNAs (miR-122 and miR-192) are promising biomarkers of acetaminophen-induced acute liver injury (APAP-ALI) in mice. We have examined these molecules, for the first time, in humans with APAP poisoning. Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients, compared to healthy controls (median ΔΔCt [25th, 75th percentile]) (miR-122: 1,265 [491, 4,270] versus 12.1 [7.0, 26.9], P < 0.0001; miR-192: 6.9 [2.0, 29.2] versus 0.44 [0.30, 0.69], P < 0.0001). A heart-enriched miR-1 showed no difference between APAP-ALI patients and controls, whereas miR-218 (brain-enriched) was slightly higher in the APAP-ALI cohort (0.17 [0.07, 0.50] versus 0.07 [0.04, 0.12]; P = 0.01). In chronic kidney disease (CKD) patients, miR-122 and -192 were modestly higher, compared to controls (miR-122: 32.0 [21.1, 40.9] versus 12.1 [7.0, 26.9], P = 0.006; miR-192: 1.2 [0.74, 1.9] versus 0.44 [0.30, 0.69], P = 0.005), but miR-122 and -192 were substantially higher in APAP-ALI patients than CKD patients (miR-122: P < 0.0001; miR-192: P < 0.0004). miR-122 correlated with peak ALT levels in the APAP-ALI cohort (Pearson R = 0.46, P = 0.0005), but not with prothrombin time. miR-122 was also raised alongside peak ALT levels in a group of patients with non-APAP ALI. Day 1 serum miR-122 levels were almost 2-fold higher in APAP-ALI patients who satisfied King's College Criteria (KCC), compared to those who did not satisfy KCC, although this did not reach statistical significance (P = 0.15).UNLABELLEDNew biomarkers of liver injury are required in the clinic and in preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver-enriched microRNAs (miR-122 and miR-192) are promising biomarkers of acetaminophen-induced acute liver injury (APAP-ALI) in mice. We have examined these molecules, for the first time, in humans with APAP poisoning. Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients, compared to healthy controls (median ΔΔCt [25th, 75th percentile]) (miR-122: 1,265 [491, 4,270] versus 12.1 [7.0, 26.9], P < 0.0001; miR-192: 6.9 [2.0, 29.2] versus 0.44 [0.30, 0.69], P < 0.0001). A heart-enriched miR-1 showed no difference between APAP-ALI patients and controls, whereas miR-218 (brain-enriched) was slightly higher in the APAP-ALI cohort (0.17 [0.07, 0.50] versus 0.07 [0.04, 0.12]; P = 0.01). In chronic kidney disease (CKD) patients, miR-122 and -192 were modestly higher, compared to controls (miR-122: 32.0 [21.1, 40.9] versus 12.1 [7.0, 26.9], P = 0.006; miR-192: 1.2 [0.74, 1.9] versus 0.44 [0.30, 0.69], P = 0.005), but miR-122 and -192 were substantially higher in APAP-ALI patients than CKD patients (miR-122: P < 0.0001; miR-192: P < 0.0004). miR-122 correlated with peak ALT levels in the APAP-ALI cohort (Pearson R = 0.46, P = 0.0005), but not with prothrombin time. miR-122 was also raised alongside peak ALT levels in a group of patients with non-APAP ALI. Day 1 serum miR-122 levels were almost 2-fold higher in APAP-ALI patients who satisfied King's College Criteria (KCC), compared to those who did not satisfy KCC, although this did not reach statistical significance (P = 0.15).This work provides the first evidence for the potential use of miRNAs as biomarkers of human drug-induced liver injury.CONCLUSIONThis work provides the first evidence for the potential use of miRNAs as biomarkers of human drug-induced liver injury. New biomarkers of liver injury are required in the clinic and in preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver‐enriched microRNAs (miR‐122 and miR‐192) are promising biomarkers of acetaminophen‐induced acute liver injury (APAP‐ALI) in mice. We have examined these molecules, for the first time, in humans with APAP poisoning. Serum miR‐122 and miR‐192 were substantially higher in APAP‐ALI patients, compared to healthy controls (median ΔΔCt [25th, 75th percentile]) (miR‐122: 1,265 [491, 4,270] versus 12.1 [7.0, 26.9], P < 0.0001; miR‐192: 6.9 [2.0, 29.2] versus 0.44 [0.30, 0.69], P < 0.0001). A heart‐enriched miR‐1 showed no difference between APAP‐ALI patients and controls, whereas miR‐218 (brain‐enriched) was slightly higher in the APAP‐ALI cohort (0.17 [0.07, 0.50] versus 0.07 [0.04, 0.12]; P = 0.01). In chronic kidney disease (CKD) patients, miR‐122 and ‐192 were modestly higher, compared to controls (miR‐122: 32.0 [21.1, 40.9] versus 12.1 [7.0, 26.9], P = 0.006; miR‐192: 1.2 [0.74, 1.9] versus 0.44 [0.30, 0.69], P = 0.005), but miR‐122 and ‐192 were substantially higher in APAP‐ALI patients than CKD patients (miR‐122: P < 0.0001; miR‐192: P < 0.0004). miR‐122 correlated with peak ALT levels in the APAP‐ALI cohort (Pearson R = 0.46, P = 0.0005), but not with prothrombin time. miR‐122 was also raised alongside peak ALT levels in a group of patients with non‐APAP ALI. Day 1 serum miR‐122 levels were almost 2‐fold higher in APAP‐ALI patients who satisfied King's College Criteria (KCC), compared to those who did not satisfy KCC, although this did not reach statistical significance (P = 0.15). Conclusion: This work provides the first evidence for the potential use of miRNAs as biomarkers of human drug‐induced liver injury. (HEPATOLOGY 2011;) New biomarkers of liver injury are required in the clinic and in preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver-enriched microRNAs (miR-122 and miR-192) are promising biomarkers of acetaminophen-induced acute liver injury (APAP-ALI) in mice. We have examined these molecules, for the first time, in humans with APAP poisoning. Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients, compared to healthy controls (median [Delta][Delta]Ct [25th, 75th percentile]) (miR-122: 1,265 [491, 4,270] versus 12.1 [7.0, 26.9], P < 0.0001; miR-192: 6.9 [2.0, 29.2] versus 0.44 [0.30, 0.69], P < 0.0001). A heart-enriched miR-1 showed no difference between APAP-ALI patients and controls, whereas miR-218 (brain-enriched) was slightly higher in the APAP-ALI cohort (0.17 [0.07, 0.50] versus 0.07 [0.04, 0.12]; P = 0.01). In chronic kidney disease (CKD) patients, miR-122 and -192 were modestly higher, compared to controls (miR-122: 32.0 [21.1, 40.9] versus 12.1 [7.0, 26.9], P = 0.006; miR-192: 1.2 [0.74, 1.9] versus 0.44 [0.30, 0.69], P = 0.005), but miR-122 and -192 were substantially higher in APAP-ALI patients than CKD patients (miR-122: P < 0.0001; miR-192: P < 0.0004). miR-122 correlated with peak ALT levels in the APAP-ALI cohort (Pearson R = 0.46, P = 0.0005), but not with prothrombin time. miR-122 was also raised alongside peak ALT levels in a group of patients with non-APAP ALI. Day 1 serum miR-122 levels were almost 2-fold higher in APAP-ALI patients who satisfied King's College Criteria (KCC), compared to those who did not satisfy KCC, although this did not reach statistical significance (P = 0.15). Conclusion: This work provides the first evidence for the potential use of miRNAs as biomarkers of human drug-induced liver injury. (HEPATOLOGY 2011;) New biomarkers of liver injury are required in the clinic and in preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver-enriched microRNAs (miR-122 and miR-192) are promising biomarkers of acetaminophen-induced acute liver injury (APAP-ALI) in mice. We have examined these molecules, for the first time, in humans with APAP poisoning. Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients, compared to healthy controls (median ΔΔCt [25th, 75th percentile]) (miR-122: 1,265 [491, 4,270] versus 12.1 [7.0, 26.9], P < 0.0001; miR-192: 6.9 [2.0, 29.2] versus 0.44 [0.30, 0.69], P < 0.0001). A heart-enriched miR-1 showed no difference between APAP-ALI patients and controls, whereas miR-218 (brain-enriched) was slightly higher in the APAP-ALI cohort (0.17 [0.07, 0.50] versus 0.07 [0.04, 0.12]; P = 0.01). In chronic kidney disease (CKD) patients, miR-122 and -192 were modestly higher, compared to controls (miR-122: 32.0 [21.1, 40.9] versus 12.1 [7.0, 26.9], P = 0.006; miR-192: 1.2 [0.74, 1.9] versus 0.44 [0.30, 0.69], P = 0.005), but miR-122 and -192 were substantially higher in APAP-ALI patients than CKD patients (miR-122: P < 0.0001; miR-192: P < 0.0004). miR-122 correlated with peak ALT levels in the APAP-ALI cohort (Pearson R = 0.46, P = 0.0005), but not with prothrombin time. miR-122 was also raised alongside peak ALT levels in a group of patients with non-APAP ALI. Day 1 serum miR-122 levels were almost 2-fold higher in APAP-ALI patients who satisfied King's College Criteria (KCC), compared to those who did not satisfy KCC, although this did not reach statistical significance (P = 0.15). This work provides the first evidence for the potential use of miRNAs as biomarkers of human drug-induced liver injury.
Author	French, Neil S. Dear, James Platt, Vivien Costello, Eithne M. Park, B. Kevin Goldring, Chris E. Antoine, Daniel J. Simpson, Kenneth J. Moggs, Jonathan Craig, Darren G.N. Neoptolemos, John P. Starkey Lewis, Philip J. Dhaun, Neeraj Webb, David J.
Author_xml	– sequence: 1 givenname: Philip J. surname: Starkey Lewis fullname: Starkey Lewis, Philip J. – sequence: 2 givenname: James surname: Dear fullname: Dear, James – sequence: 3 givenname: Vivien surname: Platt fullname: Platt, Vivien – sequence: 4 givenname: Kenneth J. surname: Simpson fullname: Simpson, Kenneth J. – sequence: 5 givenname: Darren G.N. surname: Craig fullname: Craig, Darren G.N. – sequence: 6 givenname: Daniel J. surname: Antoine fullname: Antoine, Daniel J. – sequence: 7 givenname: Neil S. surname: French fullname: French, Neil S. – sequence: 8 givenname: Neeraj surname: Dhaun fullname: Dhaun, Neeraj – sequence: 9 givenname: David J. surname: Webb fullname: Webb, David J. – sequence: 10 givenname: Eithne M. surname: Costello fullname: Costello, Eithne M. – sequence: 11 givenname: John P. surname: Neoptolemos fullname: Neoptolemos, John P. – sequence: 12 givenname: Jonathan surname: Moggs fullname: Moggs, Jonathan – sequence: 13 givenname: Chris E. surname: Goldring fullname: Goldring, Chris E. email: chrissy@liv.ac.uk – sequence: 14 givenname: B. Kevin surname: Park fullname: Park, B. Kevin
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24749860$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22045675$$D View this record in MEDLINE/PubMed
BookMark	eNp90d9qFDEUBvAgFbutXvgCEhBRL6Y9-TfJXJalWqFYEb0eMpmkzZrJbJMZZe98BJ_RJzHrrgoFe5Wb3zmHfN8ROohjtAg9JXBCAOjpjV2fUC6YeoAWRFBZMSbgAC2ASqgawppDdJTzCgAaTtUjdEgpcFFLsUBXS5_MHPTk4zUevEnjx_dnGeuM1-Nk4-R1wINOX2zKeHT4Zh50xH2ar39-_-FjPxvb4-C_2oR9XM1p8xg9dDpk-2T_HqPPb84_LS-qy6u375Znl5Xhiqiqt5xCDVTZxnLWdaRnrhGdBa5Vxw3TEhwhvaaucU7ImijK694QLYjpGAh2jF7u9q7TeDvbPLWDz8aGoKMd59w2QEFJSXiRr-6VRMq6rpWgUOjzO3Q1zimWfxRVDBVEbk8_26u5G2zfrpMvCW3aP6EW8GIPdDY6uKSj8fmf45I3qt6ee71zJfWck3V_CYF2W2xbim1_F1vs6R1r_FRaG-OUtA_3TXzzwW7-v7q9OP-wm_gF_Iyyqw
CODEN	HPTLD9
CitedBy_id	crossref_primary_10_1002_jat_3358 crossref_primary_10_1039_C5RA10112C crossref_primary_10_1093_toxsci_kfz138 crossref_primary_10_3390_ijms19123857 crossref_primary_10_3109_1354750X_2015_1101785 crossref_primary_10_1007_s00108_014_3507_9 crossref_primary_10_1007_s13277_014_2622_5 crossref_primary_10_1016_j_ijbiomac_2024_138470 crossref_primary_10_1016_j_metabol_2023_155656 crossref_primary_10_1016_j_intimp_2023_110060 crossref_primary_10_1093_toxsci_kfy282 crossref_primary_10_1007_s00204_016_1828_2 crossref_primary_10_1182_blood_2013_06_510586 crossref_primary_10_1007_s00535_024_02135_6 crossref_primary_10_1111_bcp_13136 crossref_primary_10_3109_1354750X_2012_657246 crossref_primary_10_1053_j_gastro_2013_12_032 crossref_primary_10_1038_s41598_018_27719_0 crossref_primary_10_1371_journal_pone_0172463 crossref_primary_10_2131_jts_42_73 crossref_primary_10_3390_ijms19010261 crossref_primary_10_1016_j_taap_2013_09_023 crossref_primary_10_3109_15563650_2015_1112015 crossref_primary_10_1371_journal_pone_0128076 crossref_primary_10_1007_s10928_020_09720_1 crossref_primary_10_1016_j_snb_2024_136136 crossref_primary_10_3109_1354750X_2016_1141987 crossref_primary_10_1007_s11033_024_09327_6 crossref_primary_10_1002_jat_2930 crossref_primary_10_1371_journal_pone_0052442 crossref_primary_10_1586_17474124_2016_1127756 crossref_primary_10_1002_jmv_24829 crossref_primary_10_2217_epi_12_39 crossref_primary_10_1111_bcp_15661 crossref_primary_10_1007_BF03261997 crossref_primary_10_1016_j_ajpath_2019_11_014 crossref_primary_10_1093_toxsci_kfu232 crossref_primary_10_1016_j_tiv_2019_06_002 crossref_primary_10_3390_cancers11040553 crossref_primary_10_1155_2014_393109 crossref_primary_10_1517_17425255_2014_920823 crossref_primary_10_1002_hep_27857 crossref_primary_10_1089_aivt_2015_0001 crossref_primary_10_3390_ijms17111795 crossref_primary_10_1002_hep_25558 crossref_primary_10_3109_15563650_2012_659252 crossref_primary_10_1016_S0140_6736_13_62062_0 crossref_primary_10_1097_TP_0b013e31828618d8 crossref_primary_10_1097_MEG_0000000000000157 crossref_primary_10_1186_s12864_016_2958_x crossref_primary_10_1111_imr_12055 crossref_primary_10_1093_bib_bbv056 crossref_primary_10_1186_s12893_019_0664_8 crossref_primary_10_1080_00365521_2022_2148835 crossref_primary_10_1177_1535370215605588 crossref_primary_10_1128_JVI_00955_15 crossref_primary_10_3109_1354750X_2014_944217 crossref_primary_10_1016_j_taap_2015_02_013 crossref_primary_10_1039_D4SD00031E crossref_primary_10_1016_j_biocel_2018_05_002 crossref_primary_10_1293_tox_2017_0036 crossref_primary_10_1016_j_jep_2019_111910 crossref_primary_10_1111_jcmm_13714 crossref_primary_10_1093_toxsci_kfw085 crossref_primary_10_1371_journal_pone_0066086 crossref_primary_10_1016_j_talanta_2016_08_072 crossref_primary_10_1038_s41598_017_15594_0 crossref_primary_10_1586_17512433_2014_904201 crossref_primary_10_2217_bmm_15_89 crossref_primary_10_1016_j_virusres_2014_11_023 crossref_primary_10_3390_cells13161330 crossref_primary_10_1177_0192623312448939 crossref_primary_10_1038_nrgastro_2013_87 crossref_primary_10_3390_ijms151017644 crossref_primary_10_1586_erm_12_131 crossref_primary_10_2217_bmm_15_86 crossref_primary_10_3390_antiox12040870 crossref_primary_10_1016_j_talanta_2021_122092 crossref_primary_10_1007_s13181_019_00739_6 crossref_primary_10_1517_17425255_2012_693914 crossref_primary_10_2217_bmm_2016_0338 crossref_primary_10_1097_BRS_0000000000001139 crossref_primary_10_1016_j_cca_2013_05_021 crossref_primary_10_1210_jc_2017_01417 crossref_primary_10_1002_jat_3326 crossref_primary_10_3109_1354750X_2016_1172113 crossref_primary_10_1016_j_biopha_2018_11_144 crossref_primary_10_3390_v12090965 crossref_primary_10_3390_ijms18040803 crossref_primary_10_3390_ijms23168846 crossref_primary_10_1016_j_talanta_2020_121265 crossref_primary_10_3390_livers3040039 crossref_primary_10_5812_jjnpp_65678 crossref_primary_10_1016_j_cgh_2015_06_017 crossref_primary_10_1080_14737159_2018_1508998 crossref_primary_10_3390_ijms22189799 crossref_primary_10_1038_clpt_2012_108 crossref_primary_10_1039_c7tx00340d crossref_primary_10_1016_j_scitotenv_2018_07_109 crossref_primary_10_2217_bmm_13_9 crossref_primary_10_1016_j_clinre_2016_11_001 crossref_primary_10_1038_clpt_2012_101 crossref_primary_10_1016_j_taap_2012_04_018 crossref_primary_10_3892_etm_2018_6962 crossref_primary_10_4254_wjh_v15_i1_19 crossref_primary_10_1111_1556_4029_13623 crossref_primary_10_1080_15563650_2021_1978477 crossref_primary_10_3390_ijms23010224 crossref_primary_10_1007_s00204_021_03150_9 crossref_primary_10_1111_jvh_12075 crossref_primary_10_1186_s12920_015_0136_7 crossref_primary_10_1016_j_jhep_2011_12_019 crossref_primary_10_1007_s00018_025_05748_z crossref_primary_10_1213_ANE_0000000000002444 crossref_primary_10_3390_biomedicines9091239 crossref_primary_10_1016_j_micpath_2020_104355 crossref_primary_10_1002_hep_29153 crossref_primary_10_1007_s11033_023_08666_0 crossref_primary_10_1111_liv_12322 crossref_primary_10_1002_j_2040_4603_2013_tb00507_x crossref_primary_10_1016_j_taap_2014_06_013 crossref_primary_10_1016_j_cld_2018_01_006 crossref_primary_10_1097_PAI_0000000000000125 crossref_primary_10_1007_s11259_019_09764_w crossref_primary_10_1080_17425255_2018_1539077 crossref_primary_10_1186_1471_2164_15_S3_S4 crossref_primary_10_1111_acer_13863 crossref_primary_10_1002_jcp_30908 crossref_primary_10_1016_j_pharmthera_2018_03_009 crossref_primary_10_1371_journal_pone_0188980 crossref_primary_10_14202_vetworld_2018_667_673 crossref_primary_10_1016_j_jhep_2018_04_024 crossref_primary_10_1111_jvh_12001 crossref_primary_10_1089_ars_2015_6406 crossref_primary_10_1007_s11033_022_07170_1 crossref_primary_10_1016_j_toxlet_2018_09_016 crossref_primary_10_3389_fcell_2024_1393618 crossref_primary_10_1016_j_jhep_2013_12_026 crossref_primary_10_1089_aivt_2020_0008 crossref_primary_10_3390_ijms22010382 crossref_primary_10_1016_j_ijid_2014_09_020 crossref_primary_10_1093_toxsci_kfab003 crossref_primary_10_1124_dmd_113_052670 crossref_primary_10_1124_dmd_121_000732 crossref_primary_10_1111_cts_12425 crossref_primary_10_1007_s12265_012_9368_5 crossref_primary_10_1007_s12010_019_03177_w crossref_primary_10_1517_17425255_2015_1021687 crossref_primary_10_2147_IJGM_S478709 crossref_primary_10_1080_1354750X_2018_1499128 crossref_primary_10_1016_j_jhep_2014_03_031 crossref_primary_10_1089_zeb_2013_0912 crossref_primary_10_1007_s00216_013_7340_0 crossref_primary_10_1016_j_bios_2022_114404 crossref_primary_10_1080_10408444_2021_1907530 crossref_primary_10_1200_JCO_2011_41_4557 crossref_primary_10_1002_hep_28886 crossref_primary_10_1016_j_toxlet_2013_06_158 crossref_primary_10_1016_j_clinthera_2020_05_003 crossref_primary_10_3390_ijms17071043 crossref_primary_10_1371_journal_pone_0136908 crossref_primary_10_1371_journal_pone_0125341 crossref_primary_10_1155_2018_7842064 crossref_primary_10_1016_j_bios_2017_11_047 crossref_primary_10_1039_C5TX00054H crossref_primary_10_1371_journal_pone_0220406 crossref_primary_10_1007_s00125_020_05237_x crossref_primary_10_1111_bcp_16371 crossref_primary_10_3390_medicines3030018 crossref_primary_10_1111_bcp_12699 crossref_primary_10_1016_j_tox_2020_152493 crossref_primary_10_1111_bcp_12214 crossref_primary_10_1111_bcp_15724 crossref_primary_10_1080_15563650_2017_1317349 crossref_primary_10_1038_srep23709 crossref_primary_10_1093_qjmed_hct062 crossref_primary_10_1080_17474124_2021_1857238 crossref_primary_10_1016_j_toxlet_2017_08_017 crossref_primary_10_1016_j_clinbiochem_2017_08_010 crossref_primary_10_1371_journal_pone_0066309 crossref_primary_10_1002_eji_201545787 crossref_primary_10_1515_cclm_2012_0360 crossref_primary_10_1016_j_advms_2016_05_001 crossref_primary_10_2217_bmm_15_50 crossref_primary_10_1007_s00204_015_1519_4 crossref_primary_10_1373_clinchem_2013_216044 crossref_primary_10_1080_1354750X_2016_1269131 crossref_primary_10_1016_j_taap_2017_07_019 crossref_primary_10_1080_1354750X_2018_1528631 crossref_primary_10_1016_j_talanta_2024_126108 crossref_primary_10_1517_17425255_2014_954312 crossref_primary_10_3390_nu14050962 crossref_primary_10_1002_jbt_22321 crossref_primary_10_1093_toxsci_kfs340 crossref_primary_10_3390_antiox10030390 crossref_primary_10_1007_s12072_018_9871_0 crossref_primary_10_1038_s41598_017_11811_y crossref_primary_10_1039_C4TX00051J crossref_primary_10_1088_0957_4484_24_40_405102 crossref_primary_10_1186_1479_5876_10_151 crossref_primary_10_3390_diagnostics15020179 crossref_primary_10_3390_ijms21197368 crossref_primary_10_1016_j_jss_2015_05_055 crossref_primary_10_1016_j_semnephrol_2012_04_004 crossref_primary_10_1111_jnc_12662 crossref_primary_10_1177_1535370217733425 crossref_primary_10_1016_j_ebiom_2020_103092 crossref_primary_10_1007_s00228_016_2183_1 crossref_primary_10_1124_dmd_113_052357 crossref_primary_10_1007_s40291_013_0049_0 crossref_primary_10_1177_0192623312464436 crossref_primary_10_1371_journal_pone_0048366 crossref_primary_10_4254_wjh_v5_i9_479 crossref_primary_10_1016_j_dmpk_2020_11_007 crossref_primary_10_1016_j_bcp_2019_113664 crossref_primary_10_1038_srep15501 crossref_primary_10_1146_annurev_pharmtox_011112_140250 crossref_primary_10_1016_j_toxlet_2014_01_013 crossref_primary_10_1177_0300985813505117 crossref_primary_10_1080_14728222_2022_2133699 crossref_primary_10_1134_S0026893316020072 crossref_primary_10_1002_lt_23958 crossref_primary_10_1186_1756_0500_7_702 crossref_primary_10_1016_j_jhep_2021_03_013 crossref_primary_10_3892_mmr_2021_12517 crossref_primary_10_1002_jhbp_145 crossref_primary_10_1016_j_snb_2023_135262 crossref_primary_10_1016_j_taap_2012_01_009 crossref_primary_10_1111_jcmm_12223 crossref_primary_10_1002_tox_22331 crossref_primary_10_1097_MD_0000000000013478 crossref_primary_10_1111_liv_13312 crossref_primary_10_1002_cpdd_790 crossref_primary_10_1038_sdata_2014_5 crossref_primary_10_1038_s41582_020_0362_2 crossref_primary_10_1002_hep_27349 crossref_primary_10_1038_srep19776 crossref_primary_10_3892_etm_2013_937 crossref_primary_10_1517_13543784_2014_867327 crossref_primary_10_3389_fphar_2015_00236 crossref_primary_10_1016_j_snb_2022_131743 crossref_primary_10_1074_jbc_M116_769893 crossref_primary_10_1002_jat_3722 crossref_primary_10_1016_j_isci_2025_112986 crossref_primary_10_1074_jbc_R115_708842 crossref_primary_10_1093_toxsci_kfv260 crossref_primary_10_1124_jpet_117_242081 crossref_primary_10_1111_liv_13202 crossref_primary_10_1136_gutjnl_2016_313369 crossref_primary_10_3390_s120608100 crossref_primary_10_1111_jcmm_12236 crossref_primary_10_1007_s00204_020_02682_w crossref_primary_10_1111_liv_13441 crossref_primary_10_1016_j_comtox_2020_100134 crossref_primary_10_1177_1091581817704975 crossref_primary_10_1002_lt_23377 crossref_primary_10_1097_MPG_0000000000000600 crossref_primary_10_1186_s13054_014_0704_9 crossref_primary_10_1016_j_cyto_2016_05_021 crossref_primary_10_1039_C4TX00238E crossref_primary_10_1063_5_0085078 crossref_primary_10_1111_bcp_12408 crossref_primary_10_1016_j_taap_2014_05_010 crossref_primary_10_1016_j_jceh_2013_09_001 crossref_primary_10_1111_jvh_12470 crossref_primary_10_1016_j_phrs_2017_10_002 crossref_primary_10_1586_17512433_2016_1154786 crossref_primary_10_1002_jat_2864 crossref_primary_10_3390_ijms17030280 crossref_primary_10_1016_j_ecoenv_2023_115103 crossref_primary_10_3390_jcm4051063 crossref_primary_10_3390_ijms17081232 crossref_primary_10_1002_hep_27250 crossref_primary_10_1208_s12248_018_0245_2 crossref_primary_10_1111_liv_12961 crossref_primary_10_3389_fphar_2017_00003 crossref_primary_10_1002_cld_611 crossref_primary_10_1016_j_tvjl_2016_01_010 crossref_primary_10_2217_bmm_13_42 crossref_primary_10_3389_fphar_2016_00267 crossref_primary_10_1177_1535370217731291 crossref_primary_10_1371_journal_pone_0155248 crossref_primary_10_1007_s11095_023_03519_8 crossref_primary_10_3390_ijms18020326 crossref_primary_10_1016_j_sjbs_2018_12_009 crossref_primary_10_1002_pmic_201200285 crossref_primary_10_1097_MD_0000000000002639 crossref_primary_10_1080_17425255_2023_2259787 crossref_primary_10_1038_labinvest_2016_95 crossref_primary_10_1517_14740338_2013_828032 crossref_primary_10_1002_hep_26294 crossref_primary_10_1016_j_nmd_2023_11_005 crossref_primary_10_1111_bcp_13282 crossref_primary_10_1002_hep_26296 crossref_primary_10_1007_s40291_016_0251_y crossref_primary_10_1586_17512433_2014_889564 crossref_primary_10_1038_srep13098 crossref_primary_10_1080_17474124_2016_1196133 crossref_primary_10_1089_aivt_2023_0004 crossref_primary_10_1016_j_jhep_2014_10_004 crossref_primary_10_1371_journal_pone_0255672 crossref_primary_10_1186_s12864_016_2956_z crossref_primary_10_1002_biot_202100587 crossref_primary_10_1038_ncomms13882 crossref_primary_10_1097_BRS_0000000000001226 crossref_primary_10_3748_wjg_v21_i17_5138 crossref_primary_10_1007_s00204_017_1974_1 crossref_primary_10_1016_j_drudis_2013_11_001 crossref_primary_10_1093_toxsci_kfu269 crossref_primary_10_4142_jvs_2016_17_1_45 crossref_primary_10_1016_j_bios_2023_115298 crossref_primary_10_1111_jvim_14602 crossref_primary_10_1016_j_phymed_2019_152867 crossref_primary_10_1586_17474124_2013_814901 crossref_primary_10_1002_hep_28367 crossref_primary_10_1080_17425255_2019_1642323 crossref_primary_10_1093_toxsci_kfae031 crossref_primary_10_1007_s40264_015_0367_8 crossref_primary_10_1111_jvim_15250 crossref_primary_10_1016_j_mayocp_2013_09_016 crossref_primary_10_1016_j_toxlet_2013_10_017 crossref_primary_10_1007_s40291_013_0065_0 crossref_primary_10_4254_wjh_v9_i12_586 crossref_primary_10_3109_1354750X_2014_958535 crossref_primary_10_1002_hep4_1501 crossref_primary_10_1016_j_critrevonc_2013_05_011 crossref_primary_10_1016_j_ejim_2015_12_017 crossref_primary_10_1517_17425255_2012_673587 crossref_primary_10_1097_MOG_0b013e3283528b5d crossref_primary_10_1042_BST20120019 crossref_primary_10_1039_c6tx00442c crossref_primary_10_1080_14737159_2018_1415145 crossref_primary_10_1097_BRS_0000000000001339 crossref_primary_10_1186_2050_6511_15_42 crossref_primary_10_1586_17512433_2014_880650 crossref_primary_10_1002_cpt_711 crossref_primary_10_3390_ijms21010212 crossref_primary_10_1016_j_ajpath_2015_10_003 crossref_primary_10_1038_ncomms11916 crossref_primary_10_1186_s12967_024_05726_2 crossref_primary_10_1007_s10096_025_05207_4 crossref_primary_10_3390_bios14090450 crossref_primary_10_1586_egh_12_71 crossref_primary_10_2217_bmm_13_147 crossref_primary_10_1002_jcb_27562 crossref_primary_10_2217_bmm_13_146 crossref_primary_10_1016_j_aohep_2020_03_008 crossref_primary_10_1073_pnas_1412608111 crossref_primary_10_1517_17425255_2012_724060 crossref_primary_10_1097_MD_0000000000022259 crossref_primary_10_1097_MD_0000000000018322 crossref_primary_10_1039_C3TX50077B crossref_primary_10_3390_genes5020430 crossref_primary_10_1038_clpt_2012_40 crossref_primary_10_1159_000374090 crossref_primary_10_1089_omi_2014_0106 crossref_primary_10_1371_journal_pone_0177928
Cites_doi	10.1016/j.taap.2010.02.011 10.1016/j.jhep.2008.01.019 10.1177/0961203310389841 10.1016/S0092-8674(04)00045-5 10.1373/clinchem.2010.147850 10.7326/0003-4819-137-12-200212170-00007 10.1186/1471-2164-8-166 10.1016/j.toxlet.2010.03.018 10.1093/toxsci/kfp235 10.1249/01.mss.0000222831.35897.5f 10.1161/HYPERTENSIONAHA.109.132670 10.3109/0886022X.2010.509830 10.1002/hep.20293 10.1073/pnas.0804549105 10.1016/j.ygyno.2010.07.021 10.3892/ijmm_00000173 10.1038/onc.2009.211 10.1073/pnas.1019055108 10.1016/j.abb.2007.07.023 10.4161/rna.1.2.1066 10.1101/gad.1781009 10.1016/0009-9120(90)80026-F 10.1002/hep.20948
ContentType	Journal Article
Copyright	Copyright © 2011 American Association for the Study of Liver Diseases 2015 INIST-CNRS Copyright © 2011 American Association for the Study of Liver Diseases.
Copyright_xml	– notice: Copyright © 2011 American Association for the Study of Liver Diseases – notice: 2015 INIST-CNRS – notice: Copyright © 2011 American Association for the Study of Liver Diseases.
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8
DOI	10.1002/hep.24538
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE AIDS and Cancer Research Abstracts
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1527-3350
EndPage	1776
ExternalDocumentID	3958146481 22045675 24749860 10_1002_hep_24538 HEP24538
Genre	article Research Support, Non-U.S. Gov't Controlled Clinical Trial Journal Article
GrantInformation_xml	– fundername: British Heart Foundation – fundername: Medical Research Council grantid: G0700654
GroupedDBID	--- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT 9DU AAMMB AAYXX ABJNI ACZKN ADSXY AEFGJ AFNMH AGQPQ AGXDD AHQVU AIDQK AIDYY AIQQE CITATION MEWTI O8X WXSBR IQODW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8
ID	FETCH-LOGICAL-c4818-de4206028e9e43bb1d3f95be04a8b4c3a70f11da2f9ff57618246dc1a51cb3053
IEDL.DBID	DRFUL
ISICitedReferencesCount	436
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000296443100028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0270-9139 1527-3350
IngestDate	Fri Jul 11 10:38:00 EDT 2025 Fri Jul 11 08:38:12 EDT 2025 Sat Nov 29 14:53:18 EST 2025 Mon Jul 21 06:03:18 EDT 2025 Mon Jul 21 09:18:33 EDT 2025 Tue Nov 18 22:10:07 EST 2025 Sat Nov 29 05:40:18 EST 2025 Wed Jan 22 16:20:50 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	Human Digestive diseases Hepatic disease Hepatotoxicity Gastroenterology
Language	English
License	CC BY 4.0 Copyright © 2011 American Association for the Study of Liver Diseases.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4818-de4206028e9e43bb1d3f95be04a8b4c3a70f11da2f9ff57618246dc1a51cb3053
Notes	Joint first author. Part of this work was funded by Novartis in the form of a PhD studentship (to P.S.L.) as part of the Center for Drug Safety Science supported by the Medical Research Council (grant no.: G0700654). fax: +44 (0)151 794 5540 Joint last author. Potential conflict of interest: Nothing to report. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
PMID	22045675
PQID	1766825175
PQPubID	996352
PageCount	10
ParticipantIDs	proquest_miscellaneous_902087714 proquest_miscellaneous_1776668520 proquest_journals_1766825175 pubmed_primary_22045675 pascalfrancis_primary_24749860 crossref_primary_10_1002_hep_24538 crossref_citationtrail_10_1002_hep_24538 wiley_primary_10_1002_hep_24538_HEP24538
PublicationCentury	2000
PublicationDate	November 2011
PublicationDateYYYYMMDD	2011-11-01
PublicationDate_xml	– month: 11 year: 2011 text: November 2011
PublicationDecade	2010
PublicationPlace	Hoboken
PublicationPlace_xml	– name: Hoboken – name: Hoboken, NJ – name: United States
PublicationTitle	Hepatology (Baltimore, Md.)
PublicationTitleAlternate	Hepatology
PublicationYear	2011
Publisher	Wiley Subscription Services, Inc., A Wiley Company Wiley Wolters Kluwer Health, Inc
Publisher_xml	– name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley – name: Wolters Kluwer Health, Inc
References	2010; 56 2009; 23 2007; 466 2010; 32 2004; 40 2011 2002; 12 2006; 38 2010; 245 2009; 112 2005; 42 2002; 137 2011; 77 2008; 105 2004; 1 2009; 28 2004; 116 2011; 108 1990; 23 2009; 54 2010; 119 1993; 33 2007; 8 2011; 20 2008; 48 2010; 196 2009; 106 Wang (R9-28-20241202) 2009; 106 Antoine (R2-28-20241202) 2009; 112 Wang (R19-28-20241202) 2011; 20 Arroyo (R18-28-20241202) 2011; 108 Ostapowicz (R12-28-20241202) 2002; 137 Lee (R11-28-20241202) 2004; 40 Lindblom (R24-28-20241202) 2007; 466 Koutedakis (R26-28-20241202) 1993; 33 Saheki (R27-28-20241202) 1990; 23 Skenderi (R25-28-20241202) 2006; 38 Larson (R10-28-20241202) 2005; 42 Coulouarn (R8-28-20241202) 2009; 28 LagosQuintana (R22-28-20241202) 2002; 12 Gatfield (R28-28-20241202) 2009; 23 Amacher (R3-28-20241202) 2010; 245 Chang (R6-28-20241202) 2004; 1 Ozkaya (R15-28-20241202) 2010; 32 Girard (R7-28-20241202) 2008; 48 Bartel (R4-28-20241202) 2004; 116 Dhaun (R13-28-20241202) 2009; 54 Zhang (R14-28-20241202) 2010; 56 Adler (R1-28-20241202) 2010; 196 Mitchell (R16-28-20241202) 2008; 105 Glinghammar (R23-28-20241202) 2009; 23 Wang (R20-28-20241202) 2010; 119 Liang (R5-28-20241202) 2007; 8 22213067 - Hepatology. 2012 May;55(5):1640-2; author reply 1642-3. doi: 10.1002/hep.25558.
References_xml	– volume: 54 start-page: 113 year: 2009 end-page: 119 article-title: Blood pressure‐independent reduction in proteinuria and arterial stiffness after acute endothelin‐a receptor antagonism in chronic kidney disease publication-title: Hypertension – volume: 8 start-page: 166 year: 2007 article-title: Characterization of microRNA expression profiles in normal human tissues publication-title: BMC Genomics – volume: 105 start-page: 10513 year: 2008 end-page: 10518 article-title: Circulating microRNAs as stable blood‐based markers for cancer detection publication-title: Proc Natl Acad Sci U S A – volume: 23 start-page: 621 year: 2009 end-page: 631 article-title: Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues and plasma publication-title: Int J Mol Med – volume: 466 start-page: 66 year: 2007 end-page: 77 article-title: Isoforms of alanine aminotransferases in human tissues and serum‐differential tissue expression using novel antibodies publication-title: Arch Biochem Biophys – volume: 33 start-page: 252 year: 1993 end-page: 257 article-title: Serum enzyme activities in individuals with different levels of physical fitness publication-title: J Sports Med Phys Fitness – volume: 38 start-page: 1054 year: 2006 end-page: 1057 article-title: Exertional rhabdomyolysis during a 246‐km continuous running race publication-title: Med Sci Sports Exerc – volume: 137 start-page: 947 year: 2002 end-page: 954 article-title: Results of a prospective study of acute liver failure at 17 tertiary care centers in the united states publication-title: Ann Intern Med – volume: 196 start-page: 1 year: 2010 end-page: 11 article-title: Assessment of candidate biomarkers of drug‐induced hepatobiliary injury in preclinical toxicity studies publication-title: Toxicol Lett – year: 2011 article-title: Serum miR‐122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection publication-title: Am J Gastroenterol – volume: 1 start-page: 106 year: 2004 end-page: 113 article-title: miR‐122, a mammalian liver‐specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT‐1 publication-title: RNA Biol – volume: 42 start-page: 1364 year: 2005 end-page: 1372 article-title: Acetaminophen‐induced acute liver failure: results of a united states multicenter, prospective study publication-title: Hepatology – volume: 106 start-page: 4402 year: 2009 end-page: 4407 article-title: Circulating microRNAs, potential biomarkers for drug‐induced liver injury publication-title: Proc Natl Acad Sci U S A – volume: 112 start-page: 521 year: 2009 end-page: 531 article-title: High‐mobility group box‐1 protein and keratin‐18, circulating serum proteins informative of acetaminophen‐induced necrosis, and apoptosis publication-title: Toxicol Sci – volume: 108 start-page: 5003 year: 2011 end-page: 5008 article-title: Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma publication-title: Proc Natl Acad Sci U S A – volume: 77 start-page: 1265.e9 year: 2011 end-page: 1265.e16 article-title: Circulating microRNAs (miRNA) in serum of patients with prostate cancer publication-title: Urology – volume: 116 start-page: 281 year: 2004 end-page: 297 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function publication-title: Cell – volume: 56 start-page: 1830 year: 2010 end-page: 1838 article-title: Plasma microRNA‐122 as a biomarker for viral‐, alcohol‐, and chemical‐related hepatic diseases publication-title: Clin Chem – volume: 32 start-page: 1125 year: 2010 end-page: 1127 article-title: A case of acetaminophen (paracetamol) causing renal failure without liver damage in a child and review of literature publication-title: Ren Fail – volume: 48 start-page: 648 year: 2008 end-page: 656 article-title: miR‐122, a paradigm for the role of microRNAs in the liver publication-title: J Hepatol – volume: 20 start-page: 493 year: 2011 end-page: 500 article-title: Serum and urinary free microRNA level in patients with systemic lupus erythematosus publication-title: Lupus – volume: 23 start-page: 1313 year: 2009 end-page: 1326 article-title: Integration of microRNA miR‐122 in hepatic circadian gene expression publication-title: Genes Dev – volume: 28 start-page: 3526 year: 2009 end-page: 3536 article-title: Loss of miR‐122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties publication-title: Oncogene – volume: 40 start-page: 6 year: 2004 end-page: 9 article-title: Acetaminophen and the U.S. acute liver failure study group: lowering the risks of hepatic failure publication-title: Hepatology – volume: 119 start-page: 586 year: 2010 end-page: 593 article-title: Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor publication-title: Gynecol Oncol – volume: 245 start-page: 134 year: 2010 end-page: 142 article-title: The discovery and development of proteomic safety biomarkers for the detection of drug‐induced liver toxicity publication-title: Toxicol Appl Pharmacol – volume: 12 start-page: 735 year: 2002 end-page: 739 article-title: Identification of tissue‐specific MicroRNAs from mouse publication-title: Curr Biol – volume: 23 start-page: 139 year: 1990 end-page: 141 article-title: Clearance of arginiosuccinate synthetase from the circulation in acute liver disease publication-title: Clin Biochem – volume: 245 start-page: 134142 year: 2010 ident: R3-28-20241202 article-title: The discovery and development of proteomic safety biomarkers for the detection of druginduced liver toxicity. publication-title: Toxicol Appl Pharmacol doi: 10.1016/j.taap.2010.02.011 – volume: 48 start-page: 648656 year: 2008 ident: R7-28-20241202 article-title: miR122, a paradigm for the role of microRNAs in the liver. publication-title: J Hepatol doi: 10.1016/j.jhep.2008.01.019 – volume: 20 start-page: 493500 year: 2011 ident: R19-28-20241202 article-title: Serum and urinary free microRNA level in patients with systemic lupus erythematosus. publication-title: Lupus doi: 10.1177/0961203310389841 – volume: 116 start-page: 281297 year: 2004 ident: R4-28-20241202 article-title: MicroRNAs: genomics, biogenesis, mechanism, and function. publication-title: Cell doi: 10.1016/S0092-8674(04)00045-5 – volume: 56 start-page: 18301838 year: 2010 ident: R14-28-20241202 article-title: Plasma microRNA122 as a biomarker for viral, alcohol, and chemicalrelated hepatic diseases. publication-title: Clin Chem doi: 10.1373/clinchem.2010.147850 – volume: 137 start-page: 947954 year: 2002 ident: R12-28-20241202 article-title: Results of a prospective study of acute liver failure at 17 tertiary care centers in the united states. publication-title: Ann Intern Med doi: 10.7326/0003-4819-137-12-200212170-00007 – volume: 8 start-page: 166 year: 2007 ident: R5-28-20241202 article-title: Characterization of microRNA expression profiles in normal human tissues. publication-title: BMC Genomics doi: 10.1186/1471-2164-8-166 – volume: 196 start-page: 111 year: 2010 ident: R1-28-20241202 article-title: Assessment of candidate biomarkers of druginduced hepatobiliary injury in preclinical toxicity studies. publication-title: Toxicol Lett doi: 10.1016/j.toxlet.2010.03.018 – volume: 112 start-page: 521531 year: 2009 ident: R2-28-20241202 article-title: Highmobility group box1 protein and keratin18, circulating serum proteins informative of acetaminopheninduced necrosis, and apoptosis in vivo. publication-title: Toxicol Sci doi: 10.1093/toxsci/kfp235 – volume: 12 start-page: 735739 year: 2002 ident: R22-28-20241202 article-title: Identification of tissuespecific MicroRNAs from mouse. publication-title: Curr Biol – volume: 38 start-page: 10541057 year: 2006 ident: R25-28-20241202 article-title: Exertional rhabdomyolysis during a 246km continuous running race. publication-title: Med Sci Sports Exerc doi: 10.1249/01.mss.0000222831.35897.5f – volume: 54 start-page: 113119 year: 2009 ident: R13-28-20241202 article-title: Blood pressureindependent reduction in proteinuria and arterial stiffness after acute endothelina receptor antagonism in chronic kidney disease. publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.109.132670 – volume: 32 start-page: 11251127 year: 2010 ident: R15-28-20241202 article-title: A case of acetaminophen (paracetamol) causing renal failure without liver damage in a child and review of literature. publication-title: Ren Fail doi: 10.3109/0886022X.2010.509830 – volume: 40 start-page: 69 year: 2004 ident: R11-28-20241202 article-title: Acetaminophen and the U.S. acute liver failure study group: lowering the risks of hepatic failure. publication-title: Hepatology doi: 10.1002/hep.20293 – volume: 105 start-page: 1051310518 year: 2008 ident: R16-28-20241202 article-title: Circulating microRNAs as stable bloodbased markers for cancer detection. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0804549105 – volume: 119 start-page: 586593 year: 2010 ident: R20-28-20241202 article-title: Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2010.07.021 – volume: 23 start-page: 621631 year: 2009 ident: R23-28-20241202 article-title: Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues and plasma. publication-title: Int J Mol Med doi: 10.3892/ijmm_00000173 – volume: 28 start-page: 35263536 year: 2009 ident: R8-28-20241202 article-title: Loss of miR122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. publication-title: Oncogene doi: 10.1038/onc.2009.211 – volume: 108 start-page: 50035008 year: 2011 ident: R18-28-20241202 article-title: Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1019055108 – volume: 466 start-page: 6677 year: 2007 ident: R24-28-20241202 article-title: Isoforms of alanine aminotransferases in human tissues and serumdifferential tissue expression using novel antibodies. publication-title: Arch Biochem Biophys doi: 10.1016/j.abb.2007.07.023 – volume: 1 start-page: 106113 year: 2004 ident: R6-28-20241202 article-title: miR122, a mammalian liverspecific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT1. publication-title: RNA Biol doi: 10.4161/rna.1.2.1066 – volume: 23 start-page: 13131326 year: 2009 ident: R28-28-20241202 article-title: Integration of microRNA miR122 in hepatic circadian gene expression. publication-title: Genes Dev doi: 10.1101/gad.1781009 – volume: 23 start-page: 139141 year: 1990 ident: R27-28-20241202 article-title: Clearance of arginiosuccinate synthetase from the circulation in acute liver disease. publication-title: Clin Biochem doi: 10.1016/0009-9120(90)80026-F – volume: 106 start-page: 44024407 year: 2009 ident: R9-28-20241202 article-title: Circulating microRNAs, potential biomarkers for druginduced liver injury. publication-title: Proc Natl Acad Sci U S A – volume: 42 start-page: 13641372 year: 2005 ident: R10-28-20241202 article-title: Acetaminopheninduced acute liver failure: results of a united states multicenter, prospective study. publication-title: Hepatology doi: 10.1002/hep.20948 – volume: 33 start-page: 252257 year: 1993 ident: R26-28-20241202 article-title: Serum enzyme activities in individuals with different levels of physical fitness. publication-title: J Sports Med Phys Fitness – reference: 22213067 - Hepatology. 2012 May;55(5):1640-2; author reply 1642-3. doi: 10.1002/hep.25558.
SSID	ssj0009428
Score	2.5529566
Snippet	New biomarkers of liver injury are required in the clinic and in preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver‐enriched... New biomarkers of liver injury are required in the clinic and in preclinical pharmaceutical evaluation. Previous studies demonstrate that two liver-enriched...
SourceID	proquest pubmed pascalfrancis crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	1767
SubjectTerms	Acetaminophen - poisoning Acute Disease Adolescent Adult Aged Alanine Transaminase - blood Analgesics, Non-Narcotic - poisoning Biological and medical sciences Biomarkers Biomarkers - blood Chemical and Drug Induced Liver Injury - blood Chemical and Drug Induced Liver Injury - diagnosis Chemical and Drug Induced Liver Injury - surgery Diagnostic Techniques, Digestive System Drug toxicity and drugs side effects treatment Female Gastroenterology. Liver. Pancreas. Abdomen Hepatology Humans Liver Liver Transplantation Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences MicroRNAs MicroRNAs - blood Middle Aged Pharmacology. Drug treatments Prospective Studies Toxicity: digestive system Young Adult
Title	Circulating microRNAs as potential markers of human drug‐induced liver injury
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.24538 https://www.ncbi.nlm.nih.gov/pubmed/22045675 https://www.proquest.com/docview/1766825175 https://www.proquest.com/docview/1776668520 https://www.proquest.com/docview/902087714
Volume	54
WOSCitedRecordID	wos000296443100028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1527-3350 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009428 issn: 0270-9139 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1RT9swED5BmSakaRvb2DJYZaY98JLhJHaciCfEqHhgHUJj6ltkOw7rBGmVtHveT9hv5JdwdtJUlUBC4i1SznZi39l39vn7AL7guOZCx9SXlGsMUDj1E2mkj_OgYAodZOWoE36dieEwGY3S8zU4XNyFafAhug03axluvrYGLlV9sAQN_W2mX0OG9roOGyHqLe_BxreLweXZEnOXOWpVDLyoPWBOF8BCNDzoCq8sRy-mssaeKRpKi_t8zlUX1q1Bg1dP-vrX8LJ1PclRoytbsGbKN_D8e3u4_hZ-HI8r7di8yityYxP1LoZHNZE1mU5mNqkIC9_YbJ6qJpOCOHY_klfzq9t__zGyRx3JybVN8yDj8g8O1Tu4HJz8PD71W74FXzNct_3csJDG6HCY1LBIqSCPipQrQ5lMFNORFLQIglyGRVoUGKdgaMLiXAeSB1rhvBFtQ6-clOYDEM24wooKS2OGIRhXKk4iFRipKMujVHuwv-j2TLdg5JYT4zprYJTDDDsocx3kwedOdNogcNwn1F8Zu04yZIKlSUw92F0MZtZaaZ1ZcEx7dVdwD_a612hf9tBElmYytzIoFCc8xCrIAzKpZToVImAevG_0ZNm-hfuPbQP7Th0e_oXs9OTcPXx8vOgObLo9bnc3chd6s2puPsEz_Xc2rqs-rItR0m-t4g6ykA3h
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NTtwwEB5RqFok1D8KTUupW_XAJcVJnD-pF0RZbdVlixBU3CLbcegiyK6S3Z77CH1GnqQzTjarlUCq1FukjO3EnrFn7PH3AXzEcc1jHXFX8lBjgBJyN5FGujgPxkKhg6wsdcKPQTwcJhcX6ckKfJ7fhWnwIboNN7IMO1-TgdOG9P4CNfSnmXzyBRrsA1gTqEao32tfTnvngwXorrDcqhh5cTphTufIQtzf7wovrUcbE1lj1xQNp8VdTueyD2sXod7T__v8Z_CkdT7ZQaMtz2HFlC_g0XF7vL4J3w9HlbZ8XuUlu6FUvdPhQc1kzSbjKaUVYeEbyuepajYumOX3Y3k1u7z9_Qdje9SSnF1TogcblVc4WC_hvHd0dth3W8YFVwtcud3cCJ9H6HKY1IhAKS8PijRUhguZKKEDGfPC83LpF2lRYKSCwYmIcu3J0NMKZ45gC1bLcWleAdMiVFhRQURmGISFSkVJoDwjFRd5kGoH9ub9nukWjpxYMa6zBkjZz7CDMttBDnzoRCcNBsddQrtLg9dJ-iIWaRJxB3bmo5m1dlpnBI9Jl3fj0IH33Wu0MDo2kaUZz0gGhaIk9LEKdo9MSlyncewJB7YbRVm0T4D_ETWwZ_Xh_l_I-kcn9uH1v4u-g8f9s-NBNvg6_PYG1u2Ot70puQOr02pm3sJD_Ws6qqvd1jj-AnddEOk
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7STQmF0vfDbZqqpYdc3Mi2_IJeQpIlpdvtEpqSm9Ez2ZB4jb3bc39Cf2N_SUey18tCAoXeDB5J9mhGmtHj-wA-YL-qVCbU5zSWmKDE1M-45j6OgykTGCALR53wY5SOx9nZWT7ZgE_LuzAtPkS_4GY9w43X1sF1pczeCjX0QlcfQ4YOewc2mSWRGcDm4cnwdLQC3WWOWxUzL2p3mPMlshAN9_rCa_PR_Yo3qBrTclrcFHSux7BuEho-_L_PfwQPuuCT7LfW8hg2dPkEtr522-tP4dvBtJaOz6s8J9f2qN7JeL8hvCHVbG6PFWHha3uep27IzBDH70dUvTj_8-s35vZoJYpc2YMeZFpeYmc9g9Ph0feDY79jXPAlw5nbV5qFNMGQQ-eaRUIEKjJ5LDRlPBNMRjylJggUD01uDGYqmJywRMmAx4EUOHJEz2FQzkr9EohkscCKjCUywyQsFiLJIhFoLihTUS492F3qvZAdHLllxbgqWiDlsEAFFU5BHrzvRasWg-MmoZ21zuslQ5ayPEuoB9vL3iw6P20KC49pL--msQfv-tfoYXbbhJd6trAyKJRkcYhVkFtkcst1mqYB8-BFayir9i3gf2Ib2HX2cPsvFMdHE_fw6t9F38LW5HBYjD6Pv7yGe27B212U3IbBvF7oN3BX_pxPm3qn842_6ocQZA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circulating+microRNAs+as+potential+markers+of+human+drug-induced+liver+injury&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Starkey+Lewis%2C+Philip+J&rft.au=Dear%2C+James&rft.au=Platt%2C+Vivien&rft.au=Simpson%2C+Kenneth+J&rft.date=2011-11-01&rft.issn=1527-3350&rft.eissn=1527-3350&rft.volume=54&rft.issue=5&rft.spage=1767&rft_id=info:doi/10.1002%2Fhep.24538&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon